from two matched primary tumors and a metastatic retroperitoneal lymph node into the subcutaneous space of female nude mice. The cell lines developed were compared to the patient tumor, as well as to conventional cell line models (lung tissue induced to express PD-L1 and two separate cell lines of RCC). Comparisons were made histopathologically by a pathologist and molecularly using DNA sequencing and Western blot.
INTRODUCTION AND OBJECTIVES:
Personalised medicine aims to tailor clinical management to the individual patient. We developed an in vitro 3D tumour model-tumouroid-which closely mimics the in vivo tumour microenvironment. Our aim was to test the feasibility of generating patient-specific renal cancer tumouroids to be used as personalised platforms to test drug response.
METHODS: Adult subjects with suspected or confirmed renal cell carcinoma (RCC) were prospectively enrolled at a UK tertiary centre. Multiregional tissue samples were collected after surgery, cells were extracted and grown in 2D culture. Tumouroids were manufactured by seeding cells into collagen type I hydrogels with added collagen IV, laminin and fibronectin and then subjected to plastic compression using the RAFTTM method to create dense tissue mimics (Lonza, UK). Tumouroids were cultured and treated with Pazopanib (10-40µM). A gene panel was used to confirm the presence of RCC related mutations. Response to treatment was assessed using metabolic assays (CellTiter Glo) and immunofluorescent staining for morphological characterisation in 3D, using microscopy. Treatment responses were calibrated against previously determined cell line tumouroid parameters, as strong (w50%), partial (w25%) and nonresponders (w10%). Ethics: UK REC 17/LO/1744; Trial registration: NCT03300102.
RESULTS: Fifteen participants provided informed consent for tissue donation, sampling was conducted in 12. One participant with a postoperative diagnosis of epitheloid angiomyolipoma was withdrawn. Out of 11 included participants (5 stage I, 1 stage II, 3 stage III, 2 stage IV), 7 were diagnosed with clear cell RCC, 3 with papillary RCC and 1 with unclassified RCC. Tumouroids from 9 participants (>80% success) were grown and treated, in one case tumouroids from both the primary and the metastatic site were successfully established. Three patientderived tumouroids, including two established from samples from the same participant, displayed strong response, 1 was a partial responder, and 6 were non responders.
CONCLUSIONS: This preliminary study demonstrates the feasibility of generating renal cancer patient-specific tumouroids in a timely fashion, with a high rate of success. Importantly, the parameters used were able to differentiate between responders and non-responders. The tumouroid technique has the potential to be developed as personalised tool to direct systemic therapy for renal cancer patients.
Source of Funding: NIHR i4i Invention for Innovation

MP21-09 NON-INVASIVE URINE MARKERS FOR THE DIFFERENTIATION BETWEEN RCCS AND ONCOCYTOMA
Melanie von Brandenstein*, Barbara K€ oditz, Caroline Eich, Sibel Cakir, Axel Heidenreich, Jochen W.U. Fries, Cologne, Germany INTRODUCTION AND OBJECTIVES: Recently our group showed that Vim3, a truncated variant of Vimentin, is overexpressed in oncocytoma and can be used as differentiating marker. Normally Vim3 is a marker for cells with metastasizing potential. Nevertheless, we know from unpublished data that Vim3 is responsible for mitochondrial overproduction. Oncocytoma harbors increased nonfunctional mitochondria. The second, for the differentiation used protein is called Mxi-2, Mxi-2 is the truncated version of MAPK p38, a protein which is involved in several different processes. We could show that Mxi-2 is overexpressed in clear cell RCCs. Furthermore the mechanism leading to the truncation of both proteins is known and correlates with two miRs which could both be detected in patient urine. Since the analysis of miRs is quit time consuming we wanted to know if it is possible to identify the truncated proteins in urine samples.
METHODS: Urine samples were accessed through our biobank (n[350). From 100µl urine samples, proteins were isolated and Western blot was performed. Furthermore, 50µl of each urine sample were analyzed with ELISA either for the detection of Vim3 or Mxi-2. A lateral flow assay was developed for the detection of Vim3 in urine samples.
RESULTS: With an ELISA a significant increase of Vim3 in urines from patient with oncocytoma (n[20) was detectable compared to all other subtypes of RCCs (chromophobe (n[50), papillary (n[40), clear cell RCC (n[200) and controls (n[40) (*p<0.01, **p<0.001, ***p<0.0001). Mxi-2 was predominantly overexpressed in clear cell RCCs compared to all other subtypes. Lateral flow assay of Vim3 shows two bands in case of oncocytoma indicating specificity of this test.
CONCLUSIONS: Both truncated proteins (Vim3 and Mxi-2) were detectable in patient urine samples and can be used for the differentiation between benign and malignant RCCs. The lateral flow for Vim3 shows high specificity.
Source of Funding: None
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